Trial Profile

A 12 Weeks,Multi-center,Randomized,Double-blind,Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of LP-003 in Adult Patients With Inadequately Controlled Moderate to Severe Seasonal Allergic Rhinitis Despite the Current Recommended Therapies

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Sep 2026 According to a Altruist Biologics media release, Biologics License Application (BLA) for LP-003 has been accepted by the National Medical Products Administration (NMPA) for the treatment of seasonal allergic rhinitis.
15 Dec 2025 Last checked against ClinicalTrials.gov: US National Institutes of Health
15 Dec 2025 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com